MethylGene Appoints Joseph Walewicz as Vice President, Business and Corporate Development

MethylGene Inc. has announced the appointment of Mr. Joseph Walewicz as Vice President, Business and Corporate Development.

Mr. Walewicz will be leading MethylGene's partnering and investor relations efforts. Reporting to Mr. Charles Grubsztajn, President and Chief Executive Officer, Mr. Walewicz brings over twelve years of experience as a senior healthcare equity research analyst for several prominent North American healthcare investment banks.

Prior to joining MethylGene, Mr. Walewicz was Vice President, Special Projects at Paladin Labs (TSX: PLB), a specialty pharmaceutical company, and Chief Operating Officer of Paladin's subsidiary, Paladin Biosciences.

Mr. Walewicz has an MBA from McGill University, a B.Sc. (Biochemistry) and a B.A. (Economics) from Queen's University, and is a CFA charterholder.

"We are very pleased to welcome Joe to our team," said Mr. Grubsztajn. "With more than seventeen years of experience in the biopharma sector, Joe has in depth knowledge of capital markets and the biotechnology industry, and will play a key role in the growth of the Company."

"I am very excited to be joining MethylGene at this time in the Company's history," said Mr. Walewicz.

Mr. Walewicz continued, "MethylGene has two exciting drug programs in mid-stage development, MGCD265 and MGCD290, and a strong balance sheet. I look forward to working with the management team to build a successful late-stage biotechnology company."